- |||||||||| sepofarsen (QR-110) / ProQR, QR-1123 / Ionis, ProQR
Review, Journal: RNA-based therapies in inherited retinal diseases. (Pubmed Central) - Nov 18, 2022
These RNA-based therapies bring several key advantages in the setting of IRDs, and the potential to bring meaningful vision benefit to individuals living with inherited blinding disorders. This review will examine the increasing breadth and relevance of RNA-based therapies in clinical medicine, explore the key features that make AONs suitable for treating genetic eye diseases, and provide an overview of the three-leading investigational AONs in clinical trials.
- |||||||||| QR-1123 / Ionis, ProQR
Enrollment closed, Enrollment change: AURORA: A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (clinicaltrials.gov) - May 6, 2022
P1/2, N=11, Active, not recruiting,
This review will examine the increasing breadth and relevance of RNA-based therapies in clinical medicine, explore the key features that make AONs suitable for treating genetic eye diseases, and provide an overview of the three-leading investigational AONs in clinical trials. Recruiting --> Active, not recruiting | N=35 --> 11
- |||||||||| Clinical, Review, Journal: RNA therapeutics in ophthalmology - translation to clinical trials. (Pubmed Central) - Sep 5, 2021
This review provides a detailed insight into the recent developments and clinical trials that have been conducted for several gene-silencing therapies, including ISTH0036, SYL040012, SYL1001, PF-04523655, Sirna-027, QR-110, QR-1123, QR-421a and IONIS-FB-L in glaucoma, dry eye disease, age-related macular degeneration, diabetic macular oedema and various inherited retinal diseases. Our aim is to explore the potential of these drugs whilst evaluating their associated advantages and disadvantages, and to discuss the future translation of RNA therapeutics in ophthalmology.
|
